This poster is published under an open license
. Please read the disclaimer
for further details.
Neoplasia, Image verification, Cancer, Diagnostic procedure, Contrast agent-intravenous, Ultrasound, PET-CT, Mammography, Oncology, Nuclear medicine, Breast
R. Battista1, S. Panareo2, V. Marchesi1, A. Pecchi1, B. Canossi1, P. Torricelli1; 1Modena/IT, 2Ferrara/IT
Methods and materials
We performed a retrospective analysis of all whole body 18F-FDG PET/CT done at Department of Nuclear Medicine of Ferrara University between 2004 and 2014 in which was found an incidental mammary uptake of 18F-FDG,
successively examined with clinical examination,
ultrasound and MRI if necessary.
Cases suggestive for breast cancer were investigated with biopsy (Tru-cut).
Forty-three patients (7 male,
mean age 66.28±14.7y/o) were selected.
Table 1 shows the data relating to the cases examined.
PET/CT images were acquired with an integrated PET/CT device composed of an Advance NXi PET scanner and a 16-slice Light Speed Plus CT scanner.
Before administration of 18F-FDG,
all patients fasted from midnight,
underwent blood glucose tests (glycemia <130 mg/dL) and,
to avoid artifacts caused by muscle activity,
were instructed not to do any physical activity or to talk prior to the examination.
The acquisition of images started approximately 60 min after intravenous injection of 370-555MBq (10-15 mCi) of FDG.
Between 5 and 7 bed positions were used for imaging,
depending on body height.
Images were evaluated by one radiologist and one nuclear physician together,
on a monitor in transverse,
coronal and sagittal plane,
as well as in a rotational projection display.
All 18F-FDG PET/CT findings are reviewed by a breast radiologist.
Breast 18F-FDG uptake was identified as abnormal if accumulation of 18F-FDG was focal and greater than in the background breast tissue.
In those lesions with associated 18F-FDG uptake,
the maximum standardized uptake value (SUVmax) was calculated.
SUVmax values determined have been divided into values ≥ 2,5 or values ≤ 2,5,
considering the value of 2,5 as a cut-off between potentially benign or malignant uptake.